US biotech Novavax has begun a phase 1 study of its coronavirus vaccine, as the number in clinical development reached double figures. The World Health Organization has been keeping tabs on ...

Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial and potential approval by ...

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Leading electronics maker Panasonic Corp. said Jan. 21 it has developed a box that can maintain ultracold temperatures for storing and transporting COVID-19 vaccines, one of the trickiest ...

The upfront payments are generous given the speculative value of Novavax's stand-alone adjuvanted COVID-19 vaccine. This is particularly true in view of the heavy expense Novavax endured in ...

Read Also: Why Novavax Stock Is Volatile This Week The news also intensified concerns about diminishing COVID-19 vaccine revenues and broader industry challenges as pandemic-driven demand ...

While the Novavax and the Sanofi GSK vaccines will not be part of the module, it will look at the circumstances surrounding the Covid-19 jab developed by Valneva. The UK had been due to receive ...

The Company has achieved a milestone associated with its Phase 2/3 clinical trial for its COVID-19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Novavax (NVAX) ...